With regard to cytotoxics conventionally used in ovarian cancer, neoadjuvant cisplatin increased the intra-tumoral trafficking of CD4 and CD8 T-cells in both mice models and patients with esophageal cancer [27], while paclitaxel augmented cellular immunity in patients with advanced non-small cell lung cancer by increasing circulating CD8 T-cells and IL-2-secreting CD4 T-cells [28]. This evidence concerns the gene IL2 and esophageal cancer.